- Record: found
- Abstract: found
- Article: not found
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Salim Yusuf
1 ,
Shofiqul Islam ,
Clara K Chow ,
Sumathy Rangarajan ,
Gilles Dagenais ,
Rafael Diaz ,
Rajeev Gupta ,
Roya Kelishadi ,
Romaina Iqbal ,
Alvaro Avezum ,
Annamarie Kruger ,
Raman Kutty ,
Fernando Lanas ,
Liu Lisheng ,
Li Wei ,
Patricio Lopez-Jaramillo ,
Aytekin Oguz ,
Omar Rahman ,
Hany Swidan ,
Khalid Yusoff ,
Witold Zatonski ,
Annika Rosengren ,
Koon K Teo
Oct 01 2011
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke.